PetVivo Holdings (PETV) Company Report

Analyst Earnings Quarterly Reports

Earnings summaries and quarterly performance for PetVivo Holdings.

Research analysts covering PetVivo Holdings.

Recent press releases and 8-K filings for PETV.

PetVivo Holdings Licenses Agentic Pet AI Technology

PETV

New Projects/Investments

Product Launch

PetVivo Holdings, Inc. has entered into an exclusive 10-year white-label licensing agreement with Digital Landia Holding Corp for its Agentic Pet AI technology, targeting the veterinary market.
This technology aims to reduce veterinary client acquisition costs by 90% - 98% (from $50-$150+ to $1.50-$5.00 per targeted outreach) and capture the rapidly growing Gen Z pet parent demographic.
The dual-platform, which includes 9 specialized AI diagnostic agents, is scheduled for launch in Q1 2026.
PetVivo will utilize this agreement to enter the $4.9 billion US veterinary AI market, with access to 30,000+ addressable clinics and existing relationships with 1,000+ veterinary clinics.

Oct 21, 2025, 12:00 PM

PetVivo Animal Health, Inc. Enters Vendor Partner Agreement with Veterinary Growth Partners

PETV

New Projects/Investments

Revenue Acceleration/Inflection

PetVivo Animal Health, Inc., a subsidiary of PetVivo Holdings, Inc., has entered into a Vendor Partner Agreement with Veterinary Growth Partners (VGP).
Under this agreement, VGP will actively promote PetVivo's key products, Spryng® with OsteoCushion® Technology and PrecisePRP®, to its network of over 7,300 veterinary members across the United States.
This collaboration aims to expand national availability, accelerate product adoption, and enhance purchasing efficiency for veterinary practices seeking non-pharmaceutical and regenerative solutions.
Spryng is an intra-articular injectable veterinary medical device for managing joint-related conditions, while PrecisePRP is a first-in-class, off-the-shelf platelet-rich plasma product designed for use by veterinarians.

Oct 16, 2025, 12:00 PM

PetVivo Holdings Announces Debt Conversion Agreements

PETV

PetVivo Holdings, Inc. entered into note conversion agreements to convert fourteen promissory notes with an aggregate outstanding debt of $2,018,155.
This debt, consisting of $1,850,000 in principal and $168,155 in accrued interest, was converted into 3,669,806 shares of common stock.
The effective conversion prices for the notes ranged from $0.50 to $0.75 per share.
This action eliminates over $2 million of Company debt from the balance sheet, strengthening PetVivo's financial position and allowing more resources for the commercialization of its products, SPRYNG® with OsteoCushion® Technology and Precise PRP®.